Pharmaceuticals

MEDISAN

MEDISAN released FY2025 Annual Earnings on April 27 After-Market (BJT), Actual Revenue: CNY 789.42 M, Actual EPS: CNY -1.07

MEDISAN released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 228.84 M, actual EPS CNY -0.02

MEDISAN released FY2025 Q4 earnings on April 27 After-Market BJT, actual revenue CNY 208.77 M, actual EPS CNY -0.4082

MEDISAN FY2026 Q1 Earnings Release Scheduled for April 28 After-Market BJT

MEDISAN FY2025 Annual Earnings Release Scheduled for April 28, 2026 After-Market BJT

MEDISAN released FY2025 Q3 earnings on October 24 After-Market BJT, actual revenue CNY 167.53 M, actual EPS CNY -0.3731

MEDISAN released FY2025 9 Months earnings on October 24 After-Market (BJT), actual revenue CNY 580.65 M, actual EPS CNY -0.6637

MEDISAN to Release FY2025 Q3 Earnings on October 25 After-Market BJT

MEDISAN released FY2025 Q2 earnings on August 26 After-Market BJT, actual revenue CNY 208.09 M, actual EPS CNY -0.2006

MEDISAN released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), actual revenue CNY 413.12 M, actual EPS CNY -0.29

MEDISAN to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Halong Pharmaceutical Announces International Patent for Polycystic Kidney Disease Treatment

HARBIN HANLIAN PHARMACEUTICAL RECEIVES APPROVAL FOR SUPPLEMENTARY APPLICATION OF INJECTABLE DILTIAZEM HYDROCHLORIDE

Hatsanli Announces Expected Net Loss of 98-80 Million Yuan in H1 2025

Hasi Lian's Secretary-General Liang Yanfei Sells 45,000 Shares

Hatrinity's Executives Reduce Holding by 199,000 Shares

Haither Pharmaceutical Executives Plan to Reduce Shareholding

Harbin Hsanlian Pharmaceutical's Potassium and Sodium Chloride Injection Passes Generic Drug Consistency Evaluation

Harbin Sanlian Pharmaceutical Issued a Cautionary Letter by Heilongjiang CSRC for Violation

Haston's Potassium and Sodium Chloride Injection Passes Consistency Evaluation

002900

MEDISAN announced that the company recently participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. The company's drugs, Rosuvastatin capsules and injectable Clonixin, are expected to win the bid in this centralized procurement

Zhitong

MEDISAN: The company's drugs, Rosuvastatin capsules and Chlorpromazine for injection, are expected to win the bid

002940

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit, followed by gains in Shutaishen, Asia-Pacific Pharmaceutical, Duoyi Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiya Pharmaceutical

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit

001269

688661

001255

301313

On September 30th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 7.641 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Quantity FRONTOP 301313 Pre-issue Share Restricted Circulation 33.5425 million MEDISAN 002900 Equity Incentive Restricted Circulation 1.9816 million OJing Tech 001269 Pre-issue Share Restricted Circulation 1.09 million BOFAY 001255 Pre-issue Share Restricted Circulation 6 million UIGreen 688661 1.4112 million

OJing Tech

UIGreen

BOFAY

FRONTOP

Zhitong A-share lock-up release overview | September 30

Harbin Sanlian Pharmaceutical Co., Ltd. Supervisory Board reviewed the list of individuals eligible for the lifting of restrictions under the third phase of the 2022 restricted stock incentive plan and confirmed that 166 incentive recipients meet the conditions for lifting restrictions. The Supervisory Board agreed to lift restrictions on 1,963,555 shares of restricted stock for these 166 incentive recipients, with the announcement date set for September 17, 2025

MEDISAN Pharmaceuticals: In the third phase of the 2022 incentive plan, 166 individuals can lift the sales restrictions

According to the Zhitong Finance APP, MEDISAN released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 413 million yuan, a year-on-year decrease of 21.08%. The net loss attributable to shareholders of the listed company was 92.3904 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 89.1959 million yuan. The basic loss per share was 0.29 yuan

MEDISAN released its performance for the first half of the year, turning from profit to a loss of 92.3904 million yuan

600351

688356

600774

300683

688658

The A-share innovative drug concept continues to be strong, with YABAO PHARM.CORP hitting the limit up, and JENKEM, HSGC, YKYY, MEDISAN, HITECK, and others leading in gains

Wallstreetcn

YABAO PHARM.CORP

JENKEM

HSGC

HITECK

YKYY

MEDISAN recently announced that its injectable Diltiazem Hydrochloride has passed the consistency evaluation of quality and efficacy for generic drugs by the National Medical Products Administration. This medication is primarily used to treat paroxysmal supraventricular tachycardia, atrial fibrillation, atrial flutter, and other heart diseases, as well as for emergency treatment of abnormal hypertension during surgery and hypertensive emergencies

MEDISAN: The injectable hydrochloride of Diltiazem has passed the consistency evaluation of generic drug quality and efficacy

300010

300857

300652

36Kr learned that the three major A-share indices collectively closed lower, with the Shanghai Composite Index down 0.03%, the Shenzhen Component Index down 0.22%, and the ChiNext Index down 0.22%; the steel, computer hardware, and insurance sectors weakened, with Anyang Steel and Shougang Corporation down over 3%, SHARETRONIC down over 2%, and China Pacific Insurance down over 1%; the pharmaceutical, automotive parts, and education sectors led the gains, with MEDISAN hitting the daily limit, Guangsheng Tang up over 16%, RADICAL up over 15%, and DOUSHEN up over 4%

36Kr

DOUSHEN

Sharetronic Data

RADICAL

The three major A-share indices collectively closed lower, with the pharmaceutical sector leading the gains

000513

01513

000705

In the afternoon, the pharmaceutical stocks continued to rise, with both innovative drugs and generic drugs performing well. Stocks such as LIVZON GROUP, MEDISAN, Qianhong Pharmaceutical, Wanbangde, Asia-Pacific Pharmaceutical, and ZHEJIANG ZHENYUAN all hit the daily limit, while Guangshengtang, Laimei Pharmaceutical, and Wohu Biological rose over 10%. On the news front, the National Organization for Drug Procurement Office announced the selection of the 11th batch of centralized procurement varieties on the 15th. After three stages of screening, 55 varieties were included in the reporting scope of the 11th batch of centralized procurement. The procurement rules will generally adhere to the principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition."

LIVZON GROUP

LIVZON PHARMA

ZHEJIANG ZHENYUAN

Pharmaceutical stocks continued to rise in the afternoon, with LIVZON GROUP and nearly ten other stocks hitting the daily limit

600380

002082

The innovative drug sector remains active, WBDE and MEDISAN hit the limit up in the afternoon, while LIVZON GROUP, Joincare, and Jinshi Yiyao followed suit

Joincare

WBDE

The innovative drug sector remains active, WBDE and MEDISAN saw their stocks locked in the afternoon

MEDISAN(002900.SZ)